Can a drug duo outsmart head and neck cancer?
NCT ID NCT04856631
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This trial is testing whether combining two drugs—toripalimab, an immunotherapy, and cetuximab, a targeted therapy—can shrink tumors in people with advanced head and neck squamous cell cancer. The study includes patients whose cancer has returned or spread after initial treatment, as well as those with a specific marker (PD-L1) who haven't had systemic therapy yet. The goal is to see if the combo is safe and effective in controlling the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- toripalimab and cetuximab
- What this could lead to
- If successful, this combination could offer a new treatment option for advanced head and neck cancer, potentially improving tumor shrinkage and disease control.
- What could go wrong
- This is an early-phase trial, so the combination may not work as hoped or could cause significant side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody EPI-326 enters first human trials for tough cancers
- Could less radiation be just as effective for HPV throat cancer?
- Can a pill change head and neck cancer before surgery? small study investigates.
- New drug XB010 takes on advanced cancers in first human trial
- New drug combo targets Hard-to-Treat cancers in early trial
- New injection fights head and neck cancer from the inside